Suzuki, Kenshi
Dimopoulos, Meletios A.
Takezako, Naoki
Okamoto, Shinichiro
Shinagawa, Atsushi
Matsumoto, Morio
Kosugi, Hiroshi
Yoon, Sung-Soo
Huang, Shang-Yi
Qin, Xiang
Qi, Ming
Iida, Shinsuke
Article History
Received: 18 January 2018
Revised: 8 February 2018
Accepted: 8 February 2018
First Online: 1 May 2018
Conflict of interest
: K.S. received honoraria from Celgene, Takeda, and Janssen and consulted for Takeda. M.A.D. consulted for Amgen, Janssen, Takeda, and Celgene; received honoraria from Amgen, Novartis, Celgene, Takeda, Genesis Pharmaceuticals, Janssen, and Bristol-Myers Squibb; received research funding from Janssen and Amgen; and received personal fees from Janssen, Genesis Pharmaceuticals, and Amgen. S.O. received honoraria from Celgene, Takeda, Bristol-Myers Squibb, Ono, Sanofi, Novartis, and Janssen and received research funding from Novartis, Ono, Sanofi, and Takeda. A.S. received honoraria from Celgene, Takeda, Janssen, Novartis, and Bristol-Myers Squibb. M.M. received honoraria from Celgene, Takeda, Bristol-Myers Squibb, Ono, and Janssen. S.-S.Y. received honoraria from Celgene, Takeda, and Janssen and consulted for Celgene, Takeda, and Janssen. X.Q. and M.Q. are employees of Janssen. S.I. received honoraria from Janssen, Celgene, Ono, Takeda, Novartis, and Bristol-Myers Squibb and received research funding from Celgene, Janssen, Ono, Takeda, Novartis, Bristol-Myers Squibb, Chugai, Sanofi, MSD, Kyowa Hakko Kirin, Astellas, Teijin Pharma, Toyama Chemical, Daiichi Sankyo, and Bayer. N.T., H.K., and S.-Y.H. declare that they have no conflict of interest.